The Recall Desk
HighFDA (Drugs)·D-0579-2025·Announced 2025-08-20

Glenmark carvedilol 25 mg tablets exceed the acceptable nitrosamine intake level

Carvedilol Tablets USP 25 mg from Glenmark are being recalled because of the presence of a nitrosamine, N-Nitroso Carvedilol I, above the current Acceptable Intake Level. 4,800 bottles affected.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Risk-of-harm product: a nitrosamine impurity measured above the named Acceptable Intake Level, with no injury reported in the source.

Plain-English summary

Carvedilol Tablets, USP, 25 mg, 500-count bottles, prescription only, manufactured by Glenmark Pharmaceuticals Ltd of Colvale-Bardez, Goa, India for Glenmark Pharmaceuticals, Inc. USA of Mahwah, New Jersey, NDC 68462-165-05, are being recalled. The action covers 4,800 bottles.

The stated reason is CGMP deviations: the presence of a nitrosamine, N-Nitroso Carvedilol I impurity, above the current Acceptable Intake Level. The FDA classified the action as Class II.

The affected lot is 19243104, expiring 7/31/2026. Distribution was nationwide in the USA.

Patients holding the affected lot should speak to their pharmacist or prescriber before stopping treatment, and pharmacies should follow the instructions issued by Glenmark.

The recalled product

Product
CARVEDILOL (CARVEDILOL)
Brand
CARVEDILOL
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Hazard
  • nitrosamine
  • n-nitroso-carvedilol
  • impurity-limit
  • cgmp-deviation
  • class-ii

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot#:19243104
  • Expires: 7/31/2026.

UPCs (4)

  • 0368462162019
  • 0368462163016
  • 0368462164013
  • 0368462165010

Distribution

Distributed nationwide across the United States.